A non-clinical comparative study of IL-23 antibodies in psoriasis

A non-clinical comparative study of IL-23 antibodies in psoriasis

Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability, IL-23 binding affinity, inhibitory-binding mode...

Full description

Bibliographic Details
Main Authors: Li Zhou, Yibing Wang, Qi Wan, Fei Wu, Jeffrey Barbon, Robert Dunstan, Stephen Gauld, Mark Konrad, Laura Leys, Richard McCarthy, Marian Namovic, Christine Nelson, Gary Overmeyer, Denise Perron, Zhi Su, Leyu Wang, Susan Westmoreland, Jun Zhang, Rui Zhu, Geertruida Veldman
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
IL-23
IL-12
psoriasis
autoimmune disease
risankizumab
guselkumab
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2021.1964420

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2021.1964420

Similar Items